Exos Asset Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Exos Asset Management’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,400	Closed	-$593K	–	745
2021 Q2	$593K	Sell	2,400 -232	-9%	-$57.1K	0.31%	89
2021 Q1	$641K	Buy	+2,632	New	+$646K	0.5%	54

Other funds holding EFTR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Exos Asset Management's EFTR Position: Q3 2021 in Review

Exos Asset Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 2,400 shares — an estimated $593K sold.

Exos Asset Management first reported a position in EFTR in Q1 2021 and held it in 2 quarters. The position peaked at $641K in Q1 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

Exos Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Exos Asset Management sold 2,400 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $593K.
Exos Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Exos Asset Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $641K in Q1 2021.
12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.